Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
3.370
+0.010 (0.30%)
At close: Mar 11, 2026, 4:00 PM EDT
3.360
-0.010 (-0.30%)
After-hours: Mar 11, 2026, 5:48 PM EDT

Acumen Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
-----1.44
Revenue Growth (YoY)
------15.38%
Gross Profit
-----1.44
Selling, General & Admin
19.320.2218.8212.887.281.35
Research & Development
118.9393.842.3232.3612.318
Total Operating Expenses
138.23114.0261.1445.2419.589.35
Operating Income
-138.23-114.02-61.14-45.24-19.58-7.91
Interest Income
9.1214.3210.792.390.080
Interest Expense
-4.17-4.07-0.58---
Other Non-Operating Income (Expense)
-0.021.44-1.44-0.01-81.110.59
Total Non-Operating Income (Expense)
4.9311.698.772.38-81.020.59
Pretax Income
-133.3-102.33-52.37-42.86-100.61-7.33
Net Income
-133.35-102.33-52.37-42.86-100.61-7.33
Net Income to Common
-133.35-102.33-52.37-42.86-100.61-7.33
Shares Outstanding (Basic)
60604941200
Shares Outstanding (Diluted)
60604941200
Shares Change (YoY)
1.58%23.46%19.72%102.43%4685.59%-
EPS (Basic)
-2.22-1.71-1.08-1.06-5.02-17.48
EPS (Diluted)
-2.22-1.71-1.08-1.06-5.02-17.48
Free Cash Flow
-123.75-86.23-43.09-35.31-18-7.45
Free Cash Flow Per Share
-2.05-1.44-0.89-0.87-0.90-17.78
Gross Margin
-----100.00%
Operating Margin
------550.97%
Profit Margin
------510.10%
FCF Margin
------518.80%
EBITDA
-138.05-113.84-60.95-45.07-19.58-7.91
EBIT
-138.23-114.02-61.14-45.24-19.58-7.91
EBIT Margin
------550.97%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q